Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Inclusion Criteria: * Confirmed diagnosis of iron overload, defined as serum ferritin \> 1,000 ng/mL and liver iron concentration ≥ 5 mg iron/g on tissue proton transverse relaxation rates Magnetic Resonance Imaging (MRI) * Underwent prior allogeneic hematopoietic stem cell transplantation (HSCT) using either myeloablative or reduced-intensity conditioning at least 12 months ago * No evidence of relapse or progression of the primary disease for which allogeneic HSCT was performed * Patients who have become red-cell transfusion independent (i.e., no red cell transfusions within the past 3 months) as well as patients who require red cell transfusions are eligible * Meets one of the following criteria: * Ineligible for phlebotomy (hemoglobin \< 11 g/dL, poor intravenous access, or unable to undergo phlebotomy every 4 weeks) * Have failed treatment with phlebotomy (serum ferritin \> 50% of baseline after 3 months of phlebotomy) * Refused phlebotomy * ECOG performance status of 0-2 * Life expectancy ≥ 6 months * Adequate renal function defined as serum creatinine \< or = 1.6 mg/dL and creatinine clearance of \> or = 60 ml/min calculated using the Crockcroft-Gault formula on 2 occasions within 30 days of enrollment * Sexually active men and women must use an effective method of contraception. Alternatively, women must have undergone clinically documented total hysterectomy and/or oophorectomy, or tubal ligation or be postmenopausal. * Must be able to give written informed c…